Takeda

Showing 15 posts of 242 posts found.

Takeda poised to cut sales jobs in Japan as restructuring continues

July 29, 2020
Medical Communications, Research and Development, Sales and Marketing Japan, Takeda, job cuts

Japan’s biggest drug firm Takeda is said to be mulling plans to cut back its sales operations with a new …

NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma

July 9, 2020
Sales and Marketing Adcentris, NICE, Takeda, UK

NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …

shutterstock_138095450

Takeda jettisons non-core portfolio in Asia Pacific to Celltrion for a potential $278 million

June 12, 2020
Medical Communications, Sales and Marketing Takeda, celltrion, pharma, sale

Takeda continues its mission to reduce its debt in the wake of its $49 billion acquisition of Shire in January …

fda

FDA approves Takeda’s first-line treatment option for non-small cell lung cancer

May 26, 2020
Manufacturing and Production FDA, Takeda, approval

The FDA has approved Takeda’s Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer …

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer

April 7, 2020
Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma

The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …

China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease

March 24, 2020
Manufacturing and Production Crohn's, Takeda, Takeda China

China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis …

takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

March 11, 2020
Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …

cambridge_skyline

Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts

March 9, 2020
Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma

Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …

takeda_logo_506_small

Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer

March 4, 2020
Research and Development CHMP, EMA, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s

February 28, 2020
Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab

Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …

hqdefault

Takeda acquires PvP Biologics after successful Phase 1 study of Celiac Disease treatment

February 26, 2020
Research and Development Celiac, PvP, Takeda, phase 1, phase III

Takeda has acquired PvP Biologics following the conclusion of a Phase 1 study of the investigational medicine TAK-062 for the …

entrance_takeda_i020_v1

Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

February 17, 2020
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …

china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …

Latest content